Israel, China team hopes to crack cure for advanced-stage solid tumors

Israel’s Enlivex Therapeutics announced a clinical collaboration with China’s BeiGene to evaluate the safety and efficacy of combining macrophage reprogramming and an anti-PD-1 immune checkpoint inhibitor to improve the treatment of patients with advanced-stage solid tumors. Enlivex’s Allocetra is based on technology discovered by Hadassah-University Medical Center’s Prof. Dror Mevorah. It is designed to reprogram […]

Continue Reading